Remote Ischaemic Conditioning for Post-surgical Complications in Hip Fracture (RIC-FRACTUR
Background Hip fracture affects 70,000 people in the United Kingdom (UK) and costs an estimated £1.1 billion per year to the National Health Service (NHS). Key clinical indicators, such as early surgical repair, have been shown to improve patient outcomes, however morbidity and mortality remain extremely high, reflecti
| Condition(s) | Hip Fracture |
|---|---|
| Status | Recruiting |
| Phase | NA |
| Study type | Interventional |
| Summary | Background Hip fracture affects 70,000 people in the United Kingdom (UK) and costs an estimated £1.1 billion per year to the National Health Service (NHS). Key clinical indicators, such as early surgical repair, have been shown to improve patient outcomes, however morbidity and mortality remain extremely high, reflecting the urgent need for novel therapies to enhance outcomes. Common complications include infection, cardiovascular events, falls and venous thromboembolism. Remote Ischaemic Conditioning (RIC) is a treatment whereby a blood pressure cuff is inflated around an arm or leg to above systolic pressures to occlude blood flow to the limb for short periods of time, that do not result in harm, but trigger innate mechanisms that reduce inflammation, improve organ blood flow and improve |
| Who can participate | Inclusion Criteria: * Adults (aged \> 18 years) * Participant has had a hip fracture identified on X-ray or computed tomography (CT) scan. * Qualifying hip fracture has not occurred more than 7 days prior to enrollment. * Able to give written informed consent. * In the opinion of the treating physician would be able to conform to the study protocol and procedures. Exclusion Criteria: * History or presence of significant peripheral vascular disease in the limb conditioned. * History or presence of complex neuropathic pains or peripheral neuropathy in the limb conditioned. * Presence of lymphoedema in the limb conditioned. * Presence of skin ulceration to the limb conditioned. * Uncontrolled arrhythmia, hypertension, diabetes or angina. * Third degree heart block or progressive heart failure |
| Ages | 18 Years |
| Sex | All |
| Lead sponsor | Sheffield Teaching Hospitals NHS Foundation Trust |
| Locations | Sheffield, South Yorkshire, United Kingdom |
| Start date | 2024-08-02 |
| NCT ID | NCT07178041 |
| Official listing | https://clinicaltrials.gov/study/NCT07178041 |